Paracrine Crosstalk between Fibroblasts and ER

Cancer Functional Aspects of Cell Biology Molecular Mechanism of Behavior

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
27 Sep 2019
Historique:
received: 06 07 2018
revised: 16 03 2019
accepted: 18 07 2019
pubmed: 17 8 2019
medline: 17 8 2019
entrez: 17 8 2019
Statut: ppublish

Résumé

Breast cancer-induced activated fibroblasts support tumor progression. However, the role of normal fibroblasts in tumor progression remains controversial. In this study, we used modified patient-derived organoid cultures and demonstrate that constitutively secreted cytokines from normal breast fibroblasts initiate a paracrine signaling mechanism with estrogen receptor-positive (ER

Identifiants

DOI: 10.1016/j.isci.2019.07.034 PMID: 31419632 PMC: PMC6706609
pubmed: 31419632
pii: S2589-0042(19)30261-5
doi: 10.1016/j.isci.2019.07.034
pmc: PMC6706609
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

388-401

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Nat Commun. 2016 Oct 11;7:13050
pubmed: 27725631
Oncogene. 2017 Aug;36(31):4457-4468
pubmed: 28368410
Cancer Cell. 2010 Feb 17;17(2):135-47
pubmed: 20138012
BMC Med. 2010 May 21;8:27
pubmed: 20492690
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
Cancer Res. 1999 Oct 1;59(19):5002-11
pubmed: 10519415
Nature. 2007 Oct 4;449(7162):557-63
pubmed: 17914389
Neoplasia. 2013 Mar;15(3):249-62
pubmed: 23479504
Nature. 2015 Feb 19;518(7539):422-6
pubmed: 25470049
Cell. 2014 Jul 31;158(3):564-78
pubmed: 25083868
Oncotarget. 2016 Jun 14;7(24):36842-36853
pubmed: 27167205
Cancer Res. 2015 Mar 15;75(6):963-73
pubmed: 25600648
Breast Cancer Res. 2016 Aug 11;18(1):84
pubmed: 27515302
Breast Cancer Res. 2006;8(5):R59
pubmed: 17062128
Cancer Res. 2008 Nov 1;68(21):9087-95
pubmed: 18974155
Breast Cancer Res. 2005;7(1):R46-59
pubmed: 15642169
Breast Cancer Res. 2012 Feb 07;14(1):R23
pubmed: 22314082
Nat Commun. 2018 Jan 4;9(1):66
pubmed: 29302031
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell. 2005 May 6;121(3):335-48
pubmed: 15882617
Cancer Res. 2016 Jul 15;76(14):4124-35
pubmed: 27216177
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Genes Dev. 2016 May 1;30(9):1002-19
pubmed: 27151975
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18691-6
pubmed: 25512506
Nat Cell Biol. 2014 Nov;16(11):1105-17
pubmed: 25266422
J Clin Invest. 2010 Feb;120(2):485-97
pubmed: 20051626
J Neurosci. 2017 Aug 16;37(33):7878-7892
pubmed: 28716963
Development. 2017 Mar 15;144(6):1065-1071
pubmed: 27993977
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1002-7
pubmed: 19797221
Plast Reconstr Surg. 2015 Oct;136(4):414e-25e
pubmed: 26090768
Oncotarget. 2016 May 10;7(19):28570-8
pubmed: 27086913
Cancer Cell. 2008 May;13(5):394-406
pubmed: 18455123
Cell. 2018 Jan 11;172(1-2):373-386.e10
pubmed: 29224780
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
Cancer Res. 2001 Feb 15;61(4):1320-6
pubmed: 11245428
Cancer Microenviron. 2012 Apr;5(1):83-93
pubmed: 22314376
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3372-7
pubmed: 19218449
Mol Cell. 2010 Aug 27;39(4):493-506
pubmed: 20797623
J Biol Chem. 1999 Jul 2;274(27):19301-8
pubmed: 10383440
PLoS Biol. 2013;11(8):e1001630
pubmed: 23966837
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71
pubmed: 15051869
Cell. 2012 Jul 6;150(1):165-78
pubmed: 22770218
Stem Cell Reports. 2018 Jan 9;10(1):196-211
pubmed: 29233553
FASEB J. 2007 Nov;21(13):3763-70
pubmed: 17586727
J Clin Invest. 2011 Oct;121(10):3804-9
pubmed: 21965337
Nat Rev Cancer. 2013 Nov;13(11):788-99
pubmed: 24132110

Auteurs

Sumanta Chatterjee (S)

Department of Immunology, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0T5, Canada; Research Institute of Oncology & Hematology, CancerCareManitoba, Winnipeg, MB R3E 0V9, Canada.

Vasudeva Bhat (V)

Department of Immunology, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0T5, Canada; Research Institute of Oncology & Hematology, CancerCareManitoba, Winnipeg, MB R3E 0V9, Canada.

Alexei Berdnikov (A)

Department of Surgery, Section of Plastic Surgery, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3A 1M5, Canada.

Jiahui Liu (J)

Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Guihua Zhang (G)

Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Edward Buchel (E)

Department of Surgery, Section of Plastic Surgery, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3A 1M5, Canada.

Janice Safneck (J)

Department of Pathology, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 3P5, Canada.

Aaron J Marshall (AJ)

Department of Immunology, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.

Leigh C Murphy (LC)

Research Institute of Oncology & Hematology, CancerCareManitoba, Winnipeg, MB R3E 0V9, Canada; Department of Biochemistry and Medical Genetics, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.

Lynne-Marie Postovit (LM)

Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2E1, Canada; Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Afshin Raouf (A)

Department of Immunology, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0T5, Canada; Research Institute of Oncology & Hematology, CancerCareManitoba, Winnipeg, MB R3E 0V9, Canada. Electronic address: afshin.raouf@umanitoba.ca.

Classifications MeSH